Formulation and Evaluation of Ciprofloxacin HCL Tablet
Keywords:
Introduction of Ciprofloxacin HCL tablet, mechanism of action, properties, formulation and evaluationAbstract
Ciprofloxacin HCL is a tablet made by wet granulation method. Ciprofloxacin is a broad spectrum fluoroquinolone antibiotic. It is mainly used for various bacterial infections including anthrax, biliary tract infection, bone and joint infection, gastrointestinal including traveller’s diarrhea and campylobacter enteritis, shigella, meningococcal meningitis prophylaxis, surgical infection prophylaxis, tuberculosis, leprosy and topically in the treatment of eye infections.
The prepared Ciprofloxacin hydrochloride tablet is evaluated in terms of bulk density, tapped density, angle of repose, Carr’s index and, hardness test, weight variation test, friability test and in vitro study. The result associated in the optimized batch is good to satisfactory, and having a good free-flowing property. The hardness, weight variation, and friability values are within the pharmacopeia limit. The in vitro dissolution studies show the maximum percentage of release of drug (86%) within 30 min.
References
References
1. Ciprofloxacin Hydrochloride. The American Society of
Health-System Pharmacists. Archived from the original
on 23 Sep 2015. Retrieved 23 Aug 2015.
2. Ciprofloxacin HCl Drops. WebMD. 22 Feb 2018.
Retrieved 22 Feb 2018.
3. Heidelbaugh JJ, Holmstrom H. The perils of prescribing
fluoroquinolones. The Journal of Family Practice 2013;
62(4): 191-97.
4. Prescribing Medicines in Pregnancy Database.
Australian Government. 23 Aug 2015. Archived from
the original on 8 Apr 2014.
5. Ball P. Quinolone generations: Natural history or natural
selection?” Journal of Antimicrobial Chemotherapy
2002; 46: 17-24.
6. Oliphant CM, Green GM. Quinolones: A comprehensive
review. American Family Physician 2002; 65(3): 455-64.
7. Oxford Handbook of Infectious Diseases and
Microbiology. OUP Oxford. 2009; 56. Archived from
the original on 8 Sep 2017.
8. WHO Model List of Essential Medicines (19th List)
(PDF). World Health Organization. April 2015. Archived
(PDF) from the original on 13 Dec 2016. Retrieved 8
Dec 2016.
9. Hamilton RJ. Tarascon Pharmacopoeia (15 ed.). Jones
& Bartlett Publishers 2014; 85.
10. Ciprofloxacin. International Drug Price Indicator Guide
Retrieved 24 Aug 2015.
11. Solomkin JS, Mazuski JE, Bradley JS et al. Diagnosis
and management of complicated intra-abdominal
infection in adults and children: Guidelines by the
Surgical Infection Society and the Infectious Diseases
Society of America. Clinical Infectious Diseases 2010;
50(2): 133-64.
12. Grabe M, Bjerklund-Johansen TE, Botto H, et al.
Guidelines on urological infections (PDF). European
Association of Urology 2013; Archived from the original
(PDF) on 31 Dec 2013.
13. Stevens DL, Bisno AL, Chambers HF et al. Practice
guidelines for the diagnosis and management of skin
and soft-tissue infections. Clinical Infectious Diseases
2005; 41(10): 1373-406.
14. Osmon DR, Berbari EF, Berendt AR et al. Diagnosis
and management of prosthetic joint infection: Clinical
practice guidelines by the Infectious Diseases Society
of America. Clinical Infectious Diseases 2012; 56(1):
e1-e25.
15. Gupta K, Hooton TM, Naber KG et al. International
clinical practice guidelines for the treatment of acute
uncomplicated cystitis and pyelonephritis in women:
A 2010 update by the Infectious Diseases Society of
America and the European Society for Microbiology
and Infectious Diseases. Clinical Infectious Diseases
2011; 52(5): e103-20.16. Hoogkamp-Korstanje JAA, Klein SJ. Ciprofloxacin in
acute exacerbations of chronic bronchitis. Journal
of Antimicrobial Chemotherapy 1986; 18(3): 407-13.
17. Vardakas KZ, Siempos II, Grammatikos A et al.
Respiratory fluoroquinolones for the treatment of
community-acquired pneumonia: A meta-analysis
of randomized controlled trials. Canadian Medical
Association Journal 2008; 179(12): 1269-77.
18. Donaldson PMW, Palleti AP, Carroll MP. Ciprofloxacin
in general practice. BMJ 1994; 308(6941): 1437.
19. Karageorgopoulos DE, Giannopoulou KP, Grammatikos
AP et al. Fluoroquinolones compared with ?-lactam
antibiotics for the treatment of acute bacterial
sinusitis: A meta-analysis of randomized controlled
trials. Canadian Medical Association Journal 2008;
178(7): 845-54.
20. Chow AW, Benninger MS, Brook I et al. Executive
summary: IDSA clinical practice guideline for acute
bacterial rhinosinusitis in children and adults. Clinical
Infectious Diseases 2012; 54(8): e72-e112.
21. Department of Health and Human Services. Centers
for Disease Control and Prevention. Gonococcal Isolate
Surveillance Project (GISP) Annual Report - 2003 (PDF).
USA: Center for Disease Control Nov 2004. Archived
(PDF) from the original on 24 Apr 2009. Retrieved 31
Aug 2009.
22. Hugh Y, Palmer H, Winter A. Ciprofloxacin resistant
gonorrhoea: The situation in Scotland and implications
for therapy (PDF). SCIEH Weekly Report. Scotland:
National Health Service 22 Jul 2003; 37.
23. Drlica K, Zhao X. DNA gyrase, topoisomerase IV, and
the 4-quinolones. Microbiology and Molecular Biology
Reviews 1997; 61(3): 377-92.
24. Yves P, Elisabetta L, Hongliang Z et al. et al. DNA
topoisomerases and their poisoning by anticancer
and antibacterial drugs. Chemistry & Biology 2010;
17(5): 421-33.
25. Cipro Labeling Revision 04/06/2009 Supplement 073
(PDF).
26. US Food and Drug Administration 6 Apr 2009. Archived
(PDF) from the original on 5 Jul 2010. Retrieved 8 Sep
2009.
27. Physicians’ Desk Reference. 55th ed. Montvale, NJ:
Medical Economics Co. 2001; 852.
28. O’Neil MJ (ed.). The Merck Index - An Encyclopedia of
Chemicals, Drugs, and Biologicals. Whitehouse Station,
NJ: Merck and Co., Inc. 2006; 386.
29. Physicians’ Desk Reference. 55th ed. Montvale, NJ:
Medical Economics Co. 543.
30. Physicians’ Desk Reference. 55th ed. Montvale, NJ:
Medical Economics Co. 2001; 852.
31. Khan FN, Dehghan MH. Enhanced bioavailability of
atorvastatin calcium from stabilized gastric resident
formulation, AAPS Pharm Sci Tech. 2011; 12(4): 1077-
86.
32. Veerareddy PR, Nama M, Gonugunta CR. Formulation
and evaluation of gastro retentive dosage forms of
clarithromycin. AAPS Pharm Sci Tech. 2008; 9(1): 231-
37.
33. Vardakas KZ, Siempos II, Grammatikos A et al.
Respiratory fluoroquinolones for the treatment of
community-acquired pneumonia: A metaanalysis of
randomized controlled trials. CMAJ Dec 2008; 179(12):
1269-77.
34. Arunachalam A, Sudhakar Babu AMS, Varatharajan
P. Preparation and in vitro evaluation of sustained
release tablets of Aceclofenac. International Journal
of Research in Pharmaceutical and Nano Sciences
2012; 1(1): 1-10.
35. Oishi TS, Nimmi I, Islam SMA. Comparative in vitro
bioequivalence analysis of some generic tablets of
Atorvastatin, a BCS class ii compound. Bang. Pharm.
Journal 2011; 14(1): 31-36.
36. Liberman HA. Pharmaceutical Dosage Form: Tablets,
2nd ed. I: 201-13.
37. Shah DY, Rampadhan M. Development and evaluation
of controlled release diltiazem hydrochloride
microparticles using cross-linked polymer. Drug
Development and Industrial Pharmacy 1997; 23(6):
567-74.
38. Balamurugan M, Saravanan VS, Ganesh P et al.
Development and in vitro evaluation of mucoadhesive
buccal tablets of domperidone. Research J. Pharm and
Tech. 2008; 1(4): 377-80.
1. Ciprofloxacin Hydrochloride. The American Society of
Health-System Pharmacists. Archived from the original
on 23 Sep 2015. Retrieved 23 Aug 2015.
2. Ciprofloxacin HCl Drops. WebMD. 22 Feb 2018.
Retrieved 22 Feb 2018.
3. Heidelbaugh JJ, Holmstrom H. The perils of prescribing
fluoroquinolones. The Journal of Family Practice 2013;
62(4): 191-97.
4. Prescribing Medicines in Pregnancy Database.
Australian Government. 23 Aug 2015. Archived from
the original on 8 Apr 2014.
5. Ball P. Quinolone generations: Natural history or natural
selection?” Journal of Antimicrobial Chemotherapy
2002; 46: 17-24.
6. Oliphant CM, Green GM. Quinolones: A comprehensive
review. American Family Physician 2002; 65(3): 455-64.
7. Oxford Handbook of Infectious Diseases and
Microbiology. OUP Oxford. 2009; 56. Archived from
the original on 8 Sep 2017.
8. WHO Model List of Essential Medicines (19th List)
(PDF). World Health Organization. April 2015. Archived
(PDF) from the original on 13 Dec 2016. Retrieved 8
Dec 2016.
9. Hamilton RJ. Tarascon Pharmacopoeia (15 ed.). Jones
& Bartlett Publishers 2014; 85.
10. Ciprofloxacin. International Drug Price Indicator Guide
Retrieved 24 Aug 2015.
11. Solomkin JS, Mazuski JE, Bradley JS et al. Diagnosis
and management of complicated intra-abdominal
infection in adults and children: Guidelines by the
Surgical Infection Society and the Infectious Diseases
Society of America. Clinical Infectious Diseases 2010;
50(2): 133-64.
12. Grabe M, Bjerklund-Johansen TE, Botto H, et al.
Guidelines on urological infections (PDF). European
Association of Urology 2013; Archived from the original
(PDF) on 31 Dec 2013.
13. Stevens DL, Bisno AL, Chambers HF et al. Practice
guidelines for the diagnosis and management of skin
and soft-tissue infections. Clinical Infectious Diseases
2005; 41(10): 1373-406.
14. Osmon DR, Berbari EF, Berendt AR et al. Diagnosis
and management of prosthetic joint infection: Clinical
practice guidelines by the Infectious Diseases Society
of America. Clinical Infectious Diseases 2012; 56(1):
e1-e25.
15. Gupta K, Hooton TM, Naber KG et al. International
clinical practice guidelines for the treatment of acute
uncomplicated cystitis and pyelonephritis in women:
A 2010 update by the Infectious Diseases Society of
America and the European Society for Microbiology
and Infectious Diseases. Clinical Infectious Diseases
2011; 52(5): e103-20.16. Hoogkamp-Korstanje JAA, Klein SJ. Ciprofloxacin in
acute exacerbations of chronic bronchitis. Journal
of Antimicrobial Chemotherapy 1986; 18(3): 407-13.
17. Vardakas KZ, Siempos II, Grammatikos A et al.
Respiratory fluoroquinolones for the treatment of
community-acquired pneumonia: A meta-analysis
of randomized controlled trials. Canadian Medical
Association Journal 2008; 179(12): 1269-77.
18. Donaldson PMW, Palleti AP, Carroll MP. Ciprofloxacin
in general practice. BMJ 1994; 308(6941): 1437.
19. Karageorgopoulos DE, Giannopoulou KP, Grammatikos
AP et al. Fluoroquinolones compared with ?-lactam
antibiotics for the treatment of acute bacterial
sinusitis: A meta-analysis of randomized controlled
trials. Canadian Medical Association Journal 2008;
178(7): 845-54.
20. Chow AW, Benninger MS, Brook I et al. Executive
summary: IDSA clinical practice guideline for acute
bacterial rhinosinusitis in children and adults. Clinical
Infectious Diseases 2012; 54(8): e72-e112.
21. Department of Health and Human Services. Centers
for Disease Control and Prevention. Gonococcal Isolate
Surveillance Project (GISP) Annual Report - 2003 (PDF).
USA: Center for Disease Control Nov 2004. Archived
(PDF) from the original on 24 Apr 2009. Retrieved 31
Aug 2009.
22. Hugh Y, Palmer H, Winter A. Ciprofloxacin resistant
gonorrhoea: The situation in Scotland and implications
for therapy (PDF). SCIEH Weekly Report. Scotland:
National Health Service 22 Jul 2003; 37.
23. Drlica K, Zhao X. DNA gyrase, topoisomerase IV, and
the 4-quinolones. Microbiology and Molecular Biology
Reviews 1997; 61(3): 377-92.
24. Yves P, Elisabetta L, Hongliang Z et al. et al. DNA
topoisomerases and their poisoning by anticancer
and antibacterial drugs. Chemistry & Biology 2010;
17(5): 421-33.
25. Cipro Labeling Revision 04/06/2009 Supplement 073
(PDF).
26. US Food and Drug Administration 6 Apr 2009. Archived
(PDF) from the original on 5 Jul 2010. Retrieved 8 Sep
2009.
27. Physicians’ Desk Reference. 55th ed. Montvale, NJ:
Medical Economics Co. 2001; 852.
28. O’Neil MJ (ed.). The Merck Index - An Encyclopedia of
Chemicals, Drugs, and Biologicals. Whitehouse Station,
NJ: Merck and Co., Inc. 2006; 386.
29. Physicians’ Desk Reference. 55th ed. Montvale, NJ:
Medical Economics Co. 543.
30. Physicians’ Desk Reference. 55th ed. Montvale, NJ:
Medical Economics Co. 2001; 852.
31. Khan FN, Dehghan MH. Enhanced bioavailability of
atorvastatin calcium from stabilized gastric resident
formulation, AAPS Pharm Sci Tech. 2011; 12(4): 1077-
86.
32. Veerareddy PR, Nama M, Gonugunta CR. Formulation
and evaluation of gastro retentive dosage forms of
clarithromycin. AAPS Pharm Sci Tech. 2008; 9(1): 231-
37.
33. Vardakas KZ, Siempos II, Grammatikos A et al.
Respiratory fluoroquinolones for the treatment of
community-acquired pneumonia: A metaanalysis of
randomized controlled trials. CMAJ Dec 2008; 179(12):
1269-77.
34. Arunachalam A, Sudhakar Babu AMS, Varatharajan
P. Preparation and in vitro evaluation of sustained
release tablets of Aceclofenac. International Journal
of Research in Pharmaceutical and Nano Sciences
2012; 1(1): 1-10.
35. Oishi TS, Nimmi I, Islam SMA. Comparative in vitro
bioequivalence analysis of some generic tablets of
Atorvastatin, a BCS class ii compound. Bang. Pharm.
Journal 2011; 14(1): 31-36.
36. Liberman HA. Pharmaceutical Dosage Form: Tablets,
2nd ed. I: 201-13.
37. Shah DY, Rampadhan M. Development and evaluation
of controlled release diltiazem hydrochloride
microparticles using cross-linked polymer. Drug
Development and Industrial Pharmacy 1997; 23(6):
567-74.
38. Balamurugan M, Saravanan VS, Ganesh P et al.
Development and in vitro evaluation of mucoadhesive
buccal tablets of domperidone. Research J. Pharm and
Tech. 2008; 1(4): 377-80.
Downloads
Published
2018-09-11
Issue
Section
Research Article
